Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NanoRepro AGFRA:NN6 -1.40%70 EV-to-EBIT is -7.15 as of Aug. 30, 2026. GuruFocus rates FRA:NN6 with a GF Score™ of 70/100 and a GF Value™ of €1.13 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 107 Medical Diagnostics & Research companies, NanoRepro AG ranks worse than 934578.5% on this metric.
The historical rank and industry rank for NanoRepro AG's EV-to-EBIT or its related term are showing as below:
FRA:NN6'
s EV-to-EBIT Range Over the Past 10 Years
Min: -28.45 Med: -3.08 Max: 57.07
Current: -7.15
During the past 13 years, the highest EV-to-EBIT of NanoRepro AG was 57.07. The lowest was -28.45. And the median was -3.08.
FRA:NN6's EV-to-EBIT is ranked worse than 100% of 107
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.15
vs FRA:NN6: -7.15
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NanoRepro AG's Enterprise Value for the quarter that ended in Jun. 2025 was €11.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NanoRepro AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-2.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG EV-to-EBIT Related Terms
NanoRepro AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, NanoRepro AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's EV-to-EBIT falls into.
NanoRepro AG's current Enterprise Value is €14.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NanoRepro AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-2.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (FRA:NN6) has a EV-to-EBIT of -7.15 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #999999 out of 107 companies in the Medical Diagnostics & Research industry.
Is NanoRepro AG's EV-to-EBIT too high?
NanoRepro AG's current EV-to-EBIT is -7.15. Based on the distribution chart, NanoRepro AG ranks #999999 out of 107 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, NanoRepro AG has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #999999 out of 107 companies for EV-to-EBIT. This places NanoRepro AG in the lower half of its industry. The industry median EV-to-EBIT is 23.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.15, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current EV-to-EBIT is -7.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (FRA:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.13, compared to a current price of €1.76 — trading 55.3% above its estimated fair value. The current EV-to-EBIT is -7.15. NanoRepro AG's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For NanoRepro AG (FRA:NN6), the current EV-to-EBIT is -7.15 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (FRA:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €1.76 is trading 55.3% above its estimated GF Value™ of €1.13.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for FRA:NN6:
EV-to-EBIT: -7.15
GF Value™: €1.13 vs. price of €1.76 (55.3% above fair value)
No single metric tells the full story. See the FRA:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
70GF Score
Get the complete analysis for FRA:NN6
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NN6 has been successfully added to your 
